MCID: EXC002
MIFTS: 41

Exocrine Pancreatic Insufficiency

Categories: Endocrine diseases

Aliases & Classifications for Exocrine Pancreatic Insufficiency

MalaCards integrated aliases for Exocrine Pancreatic Insufficiency:

Name: Exocrine Pancreatic Insufficiency 12 55 44 15 72

Classifications:



External Ids:

Disease Ontology 12 DOID:13316
MeSH 44 D010188
NCIt 50 C84316
SNOMED-CT 68 47367009
ICD10 33 K86.81
UMLS 72 C0267963

Summaries for Exocrine Pancreatic Insufficiency

MalaCards based summary : Exocrine Pancreatic Insufficiency is related to johanson-blizzard syndrome and cystic fibrosis. An important gene associated with Exocrine Pancreatic Insufficiency is COX4I2 (Cytochrome C Oxidase Subunit 4I2), and among its related pathways/superpathways are Embryonic and Induced Pluripotent Stem Cell Differentiation Pathways and Lineage-specific Markers and Gastric acid production. The drugs Fludarabine and alemtuzumab have been mentioned in the context of this disorder. Affiliated tissues include Pancreas, testes and pancreas, and related phenotypes are digestive/alimentary and endocrine/exocrine gland

Wikipedia : 75 Exocrine pancreatic insufficiency (EPI) is the inability to properly digest food due to a lack of... more...

Related Diseases for Exocrine Pancreatic Insufficiency

Diseases related to Exocrine Pancreatic Insufficiency via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 128)
# Related Disease Score Top Affiliating Genes
1 johanson-blizzard syndrome 33.1 UBR1 CFTR
2 cystic fibrosis 31.3 SPINK1 PNLIP CFTR
3 pancreatic agenesis 30.6 PTF1A PDX1
4 pancreatic agenesis 1 30.5 SPINK1 SCT PNLIP PDX1 CFTR
5 duodenal atresia 30.1 SCT CFTR
6 diabetes mellitus, permanent neonatal 30.1 PTF1A PDX1
7 neonatal diabetes mellitus 29.7 PTF1A PDX1
8 steatorrhea 29.7 SCT PNLIP CFTR CCK
9 pancreatic steatorrhea 29.6 SCT PNLIP CCK
10 alcoholic pancreatitis 28.9 SPINK1 SCT CFTR CCK
11 pancreatitis 28.5 SPINK1 SCT PNLIP CFTR CCK
12 acute pancreatitis 28.4 SPINK1 SCT PNLIP CFTR CCK
13 pancreas disease 27.4 SPINK1 SCT PTF1A PNLIP CFTR CCK
14 exocrine pancreatic insufficiency, dyserythropoietic anemia, and calvarial hyperostosis 13.0
15 shwachman-diamond syndrome 1 12.1
16 poikiloderma, hereditary fibrosing, with tendon contractures, myopathy, and pulmonary fibrosis 11.6
17 pancreatic agenesis 2 11.4
18 diarrhea 10.6
19 pancreatic cancer 10.6
20 overgrowth syndrome 10.5
21 celiac disease 1 10.5
22 diabetes mellitus 10.5
23 neutropenia 10.4
24 dysostosis 10.3
25 fibrosis of extraocular muscles, congenital, 1 10.3
26 alcohol use disorder 10.3
27 irritable bowel syndrome 10.3
28 pyle disease 10.2
29 vitamin b12 deficiency 10.2
30 lipomatosis 10.2
31 liver cirrhosis 10.2
32 intestinal disease 10.2
33 hypoglycemia 10.2
34 biliary dyskinesia 10.2 SCT CCK
35 duodenogastric reflux 10.2 SCT CCK
36 pancreatic cholera 10.1 SCT CCK
37 autoimmune disease 10.1
38 neurofibromatosis, type iv, of riccardi 10.1
39 diabetes mellitus, ketosis-prone 10.1
40 deficiency anemia 10.1
41 tropical sprue 10.1
42 autonomic neuropathy 10.1
43 pancytopenia 10.1
44 gonadal dysgenesis 10.1
45 ichthyosis 10.1
46 ectodermal dysplasia 10.1
47 cutis laxa 10.1
48 turner syndrome 10.1
49 gastritis 10.1
50 hyperglycemia 10.1

Graphical network of the top 20 diseases related to Exocrine Pancreatic Insufficiency:



Diseases related to Exocrine Pancreatic Insufficiency

Symptoms & Phenotypes for Exocrine Pancreatic Insufficiency

MGI Mouse Phenotypes related to Exocrine Pancreatic Insufficiency:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.8 CFTR PDX1 PNLIP PTF1A SPINK1 UBR1
2 endocrine/exocrine gland MP:0005379 9.73 CCK CFTR PDX1 PTF1A SPINK1 UBR1
3 growth/size/body region MP:0005378 9.7 CFTR COX4I2 PDX1 PNLIP PTF1A SPINK1
4 homeostasis/metabolism MP:0005376 9.56 CCK CFTR COX4I2 PDX1 PNLIP PTF1A
5 no phenotypic analysis MP:0003012 9.02 CCK CFTR PDX1 PTF1A SPINK1

Drugs & Therapeutics for Exocrine Pancreatic Insufficiency

Drugs for Exocrine Pancreatic Insufficiency (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 86)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fludarabine Approved Phase 2, Phase 3 21679-14-1, 75607-67-9 30751
2
alemtuzumab Approved, Investigational Phase 2, Phase 3 216503-57-0
3
Cyclophosphamide Approved, Investigational Phase 2, Phase 3 50-18-0, 6055-19-2 2907
4
Busulfan Approved, Investigational Phase 2, Phase 3 55-98-1 2478
5
Vidarabine Approved, Investigational Phase 2, Phase 3 24356-66-9 21704 32326
6
Sargramostim Approved, Investigational Phase 2, Phase 3 83869-56-1, 123774-72-1
7
Lenograstim Approved, Investigational Phase 2, Phase 3 135968-09-1
8 Pharmaceutical Solutions Phase 3
9 Alkylating Agents Phase 2, Phase 3
10 Antilymphocyte Serum Phase 2, Phase 3
11 Immunosuppressive Agents Phase 2, Phase 3
12 Antirheumatic Agents Phase 2, Phase 3
13 Antineoplastic Agents, Alkylating Phase 2, Phase 3
14 Antimetabolites Phase 2, Phase 3
15 Anti-Infective Agents Phase 2, Phase 3
16 Antimetabolites, Antineoplastic Phase 2, Phase 3
17 Antiviral Agents Phase 2, Phase 3
18 Adjuvants, Immunologic Phase 2, Phase 3
19 Antineoplastic Agents, Immunological Phase 2, Phase 3
20
Omeprazole Approved, Investigational, Vet_approved Phase 2 73590-58-6 4594
21
Mycophenolic acid Approved Phase 2 24280-93-1 446541
22
Tacrolimus Approved, Investigational Phase 2 104987-11-3 445643 439492 6473866
23
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
24
leucovorin Approved Phase 2 58-05-9 143 6006
25
Melphalan Approved Phase 2 148-82-3 460612 4053
26
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
27
Choline Approved, Nutraceutical Phase 2 62-49-7 305
28
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
29
Emodepside Investigational, Vet_approved Phase 2 155030-63-0
30 Bile Acids and Salts Phase 2
31 Omega 3 Fatty Acid Phase 2
32 alanine Phase 2
33 Flax Phase 2
34 Soy Bean Phase 2
35 Nootropic Agents Phase 2
36 Sunflower Phase 2
37 Lipid Regulating Agents Phase 2
38 Hypolipidemic Agents Phase 2
39 Lecithin Phase 2
40 Antacids Phase 2
41 Proton Pump Inhibitors Phase 2
42 Anti-Ulcer Agents Phase 2
43 Folic Acid Antagonists Phase 2
44 Nucleic Acid Synthesis Inhibitors Phase 2
45 Anti-Bacterial Agents Phase 2
46 Vitamin B9 Phase 2
47 Vidarabine Phosphate Phase 2
48 Antitubercular Agents Phase 2
49 Antibiotics, Antitubercular Phase 2
50 Vitamin B Complex Phase 2

Interventional clinical trials:

(show top 50) (show all 93)
# Name Status NCT ID Phase Drugs
1 Evaluation of the Digestive and Metabolic Utilisation of Dietary Protein in Patients With Chronic Pancreatitis Completed NCT00957151 Phase 4 Creon
2 An Open-Label Study Evaluating the Efficacy and Safety of Liprotamase in Subjects With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis Completed NCT02823964 Phase 4 Liprotamase
3 A Multicenter, Open-Label, Safety Extension of Study PR-011 Titled: A Multicenter, Randomized, Open-Label, Crossover Study to Evaluate the Mode of Administration and Safety of EUR-1008 in Infants 1 to 12 Months of Age With Exocrine Pancreatic Insufficiency (EPI) Associated With Cystic Fibrosis (CF) Completed NCT01131507 Phase 4 EUR-1008 (APT-1008)
4 An Open-label, Multicenter, Randomized, Cross-over Study to Compare the Safety and Efficacy of PANZYTRAT® 25,000 to KREON® 25,000 in the Control of Steatorrhea in Subjects Aged 7 Years and Older With Cystic Fibrosis (CF) and Exocrine Pancreatic Insufficiency (EPI) Completed NCT01327703 Phase 4 Panzytrat® 25,000;Kreon® 25,000
5 A Multicenter, Randomized, Open-Label, Crossover Study to Evaluate the Mode of Administration and Safety of EUR-1008 in Infants 1 to 12 Months of Age With Exocrine Pancreatic Insufficiency (EPI) Associated With Cystic Fibrosis (CF) Completed NCT01100606 Phase 4 EUR-1008 (APT-1008);EUR-1008 (APT-1008)
6 One Week Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multi-Center Study With Creon® 25000 Minimicrospheres™ in Subjects With Pancreatic Exocrine Insufficiency After Pancreatic Surgery, Followed by an Open-Label Long-Term Extension of 1 Year Completed NCT00535756 Phase 4 Creon;Placebo
7 Enzyme Substitution in Exocrine Pancreatic Insufficiency; Self Administration Against a Fixed Dose Regimen Completed NCT01430234 Phase 4 Panzytrat 25.000 FIP-E units of Lipase
8 MALABSORPTION BLOOD TEST: Toward a Novel Approach to Quantify Steatorrhea Completed NCT00572975 Phase 4
9 H.O.P.E. Healing Optimization Through Preoperative Engagement: A Prospective Single Cohort Study to Evaluate the Effect of a Prehabilitation Program on Preoperative Outcomes in Upper GI Surgical Oncology Patients Enrolling by invitation NCT03642093 Phase 4
10 Creon (Pancrelipase) Therapy for Subjects With Exocrine Pancreatic Insufficiency (EPI) Due to Pancreatic Cancer: A Double-blind, Randomized, Parallel Design With 2 Dose Cohorts of Pancrelipase in Resected Pancreatic Cancer Subjects and an Open-label Single Dose Cohort in Non-resected Pancreatic Cancer Subjects Not yet recruiting NCT03859869 Phase 4 Pancrelipase;Placebo
11 A Phase 4 Study to Compare US Marketed Creon Drug Product With Drug Product Manufactured With a Modernized Process at an Alternate Manufacturing Site, in Subjects With Exocrine Pancreatic Insufficiency (EPI) Due to Cystic Fibrosis Not yet recruiting NCT03924947 Phase 4 Pancrelipase
12 Intraduodenal Aspiration Study to Assess the Bioavailability of Oral Pancrecarb® Compared to Placebo Control in Patients With Pancreatic Insufficiency Terminated NCT00744250 Phase 4 Pancrelipase
13 Randomized, Double Blind, Placebo-controlled Trial of Creon in Patients With Low Faecal Pancreatic Elastase Terminated NCT01865695 Phase 4 Creon
14 A Double-blind, Randomized, Multi-center, Placebo-controlled, Parallel-group Study to Assess the Effect of Creon® on Pancreatic Exocrine Insufficiency in Subjects With Diabetes Mellitus Type 2 Withdrawn NCT02009410 Phase 4 Creon;Creon 25000 matching Placebo
15 Exocrine Pancreatic Insufficiency in Pancreatic Cancer: Evaluating the Need and Efficacy of Pancreatic Enzyme Replacement Therapy Withdrawn NCT01401387 Phase 4
16 Clinical Non-Inferiority of Pancreatic Enzymes (Norzyme ® - Bergamo) Compared To Creon ® (Solvay Pharmaceutical) in Patients With Exocrine Pancreatic Insufficiency Unknown status NCT01012908 Phase 2, Phase 3
17 An Open-Label Clinical Study Evaluating the Long-Term Safety of ALTU-135 for the Treatment of Patients With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency Completed NCT00449904 Phase 3 Liprotamase
18 A Phase 3, Open-Label Study Evaluating the Efficacy and Safety of Liprotamase in Subjects With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency Completed NCT02734810 Phase 3 Liprotamase Powder for Oral Solution
19 A Randomised, Double-Blind, Active-Controlled, Two-Treatment, Crossover, Multinational, Multicentre Study to Compare Two Pancreatic Enzyme Products in the Treatment of Exocrine Pancreatic Insufficiency in Subjects With Cystic Fibrosis Completed NCT01641393 Phase 3 EUR-1008 25,000 Units;Kreon 25,000 Units
20 A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Study Evaluating the Efficacy and Safety of ALTU-135 Treatment in Patients With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency Completed NCT00449878 Phase 3 Liprotamase;Placebo
21 A Study to Investigate the Effect of Delayed Release Pancrelipase on Maldigestion in Patients With Exocrine Pancreatic Insufficiency Due to Chronic Pancreatitis and Pancreatectomy Completed NCT00414908 Phase 3 Pancrelipase delayed release capsule;Placebo Comparator
22 An Open-Label Study to Evaluate the Efficacy and Safety of Pancreatic Enzyme Product (PEP) Microtabs in Pediatric Patients With Cystic Fibrosis and Exocrine Pancreatic Insufficiency Completed NCT00981214 Phase 3 EUR-1008 (APT-1008)
23 A Double-blind, Placebo-controlled, Parallel-group, Comparative Study to Confirm the Safety and Efficacy of Oral 1.5 g/Day and 3.0 g/Day of SA-001 in Patients With Pancreatic Exocrine Insufficiency Caused by Chronic Pancreatitis or by Pancreatectomy Completed NCT00400842 Phase 3 SA-001;SA-001;Placebo
24 A Phase 3, Randomized, Open-Label, Assessor-Blind, Noninferiority, Active-Comparator Study Evaluating the Efficacy and Safety of Liprotamase in Subjects With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency Completed NCT02279498 Phase 3 Liprotamase;porcine (pig) PERT
25 A Multicenter, Randomized, Double-Blind, Crossover Study to Compare the Safety and Efficacy of Ultrase® MT20 to Placebo for the Correction of Steatorrhea in Patients With Cystic Fibrosis (CF) Completed NCT00408317 Phase 3 Ultrase® MT20;Placebo
26 A Double-blind, Randomized, Multicenter, Cross-over Study to Compare the Effect of Creon N and Creon® on Fat Digestion in Subjects ≥ 12 Years of Age With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis Completed NCT02137382 Phase 3 Creon®;Creon N
27 A Double-blind, Randomized, Multi-center, Placebo-controlled, Cross-over Study to Assess the Efficacy and Safety of Pancrelipase Delayed Release 12,000 Unit Capsules in Subjects Aged 7 - 11 With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis Completed NCT00690820 Phase 3 Pancrelipase Delayed Release;Placebo Comparator
28 An Open Label, Multi-center, Study to Assess the Safety and Tolerability of Pancrelipase Delayed Release Capsules in Infants and Children Less Than 7 Years of Age With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis Completed NCT00775528 Phase 3 Pancrelipase Delayed Release
29 A Multicenter, Randomized, Double-blind, Parallel, Placebo-controlled, Phase III Study to Assess the Safety and Efficacy of Viokase® 16 for the Correction of Steatorrhea in Patients With Exocrine Pancreatic Insufficiency Completed NCT00559364 Phase 3 Viokase® 16;Placebo;Proton pump inhibitor (PPI);Omeprazole
30 A Double-blind, Randomized, Multi-center, Placebo-controlled, Cross-over Study to Assess the Efficacy and Safety of Pancrelipase Delayed Release 24,000 Unit Capsules in Subjects With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis Completed NCT00510484 Phase 3 Pancrelipase Delayed Release;Placebo Comparator
31 A Randomized Double-blind (Withdrawal) Phase 3 Study to Evaluate the Efficacy and Tolerability of Pancrelipase MT Capsules Compared With Placebo in the Treatment of Subjects With Cystic Fibrosis-dependent Exocrine Pancreatic Insufficiency Completed NCT00662675 Phase 3 Pancrease MT 10.5, or MT 21;Placebo for Pancrease MT 10.5 or MT 21
32 A One-year Open-label Study to Assess the Safety of Oral Long-term Use of SA-001 in Patients With Pancreatic Exocrine Insufficiency Caused by Chronic Pancreatitis or by Pancreatectomy Completed NCT00401076 Phase 3 SA-001
33 A One Week Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multi-Center Study With Creon 40,000 MMS in Subjects With Pancreatic Exocrine Insufficiency Due to Chronic Pancreatitis, Followed by an Open-Label Long-Term Extension Completed NCT00705978 Phase 3 Pancreatin;Placebo
34 A Randomized, Double-Blind, Placebo-Controlled, Two-Treatment, Crossover Study to Evaluate the Safety and Efficacy of Eurand Pancreatic Enzyme Product (PEP) in Patients With Cystic Fibrosis and Exocrine Pancreatic Insufficiency Completed NCT00297167 Phase 3 EUR-1008 (APT-1008);Placebo;Placebo;EUR-1008 (APT-1008)
35 A Randomized, Double-Blind, Dose Response-Control, Crossover Study to Evaluate the Safety and Efficacy of Two Doses of EUR-1008 in Chronic Pancreatitis (CP) Patients With Exocrine Pancreatic Insufficiency (EPI) Completed NCT00788593 Phase 3 Placebo;EUR-1008 (APT-1008) High Dose;EUR-1008 (APT-1008) Low Dose
36 A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Crossover Study to Evaluate the Effectiveness and Safety of PANCRECARB® MS-16 (Pancrelipase) in Reducing Steatorrhea in Children and Adults With Cystic Fibrosis Completed NCT00432861 Phase 3 PANCRECARB® (pancrelipase);Placebo
37 An Open Label, Multicenter Study Evaluating Safety and Tolerability of Creon Micro in Pediatric Subjects From at Least One Month to Less Than Four Years of Age With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis Completed NCT01747330 Phase 3 Pancreatin
38 Efficacy and Safety of Ultrase MT12 in the Control of Steatorrhea in Cystic Fibrosis (CF) and Pancreatic Insufficient (PI) Children Aged 2 to 6 Years Old Completed NCT00880100 Phase 3 Ultrase® MT12
39 Bone Marrow Transplantation for Non-Malignant Congenital Bone Marrow Failure Disorders Completed NCT00176878 Phase 2, Phase 3 Fludarabine monophosphate;Busulfan
40 Efficacy and Safety of Ultrase® MT20 in Improving the Coefficient of Fat Absorption (CFA%) in Children With Cystic Fibrosis (CF) and Pancreatic Insufficiency (PI) Completed NCT00513682 Phase 3 Ultrase® MT20
41 Open-label, Multicenter, Randomized, Cross-Over, Equivalence Study to Compare the Efficacy and Safety of Two Strengths of Pancreatin Enteric-Coated Capsules in Pancreatic Exocrine Insufficiency in Chinese Subjects Recruiting NCT03450772 Phase 3 Creon® 25000;Creon® 10000
42 A Phase 3, Randomized, Open-Label, Assessor-Blind, Non-Inferiority, Active-Comparator Study Evaluating the Efficacy and Safety of Liprotamase in Subjects With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency Active, not recruiting NCT03051490 Phase 3 Liprotamase;porcine PERT
43 Allogeneic Hematopoietic Stem Cell Transplant for Patients With High Risk Hemoglobinopathy Using a Preparative Regimen to Achieve Stable Mixed Chimerism Active, not recruiting NCT00176852 Phase 2, Phase 3 Busulfan, Fludarabine, ATG, TLI;Busulfan, Cyclophosphamide, ATG, GCSF;Campath, Fludarabine, Cyclophosphamide
44 An Open-Label Clinical Study Evaluating the Long Term Safety of ALTU-135 in the Treatment of Patients With Exocrine Pancreatic Insufficiency Due to Chronic Pancreatitis or Pancreatectomy Terminated NCT00500084 Phase 3 Liprotamase
45 A Randomized, Double-blind, Multicenter, Two-period Crossover Study to Assess the Efficacy and Tolerability of NM-BL (Burlulipase) in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis Completed NCT01710644 Phase 1, Phase 2 Burlulipase;Placebo (Caramel in sterile water)
46 A Phase 2, Randomized, Double Blind, Parallel Dose Ranging Study of Oral TheraCLEC™ - Total in Cystic Fibrosis Subjects With Exocrine Pancreatic Insufficiency Completed NCT00095732 Phase 2 Liprotamase;Placebo
47 A Multicentre Open-label Phase IIa Study With Escalating Dose of MS1819- SD, to Investigate the Efficacy and Safety of a Yarrowia Lipolytica Lipase Preparation for the Compensation of Exocrine Pancreatic Insufficiency Caused by Chronic Pancreatitis and/or Distal Pancreatectomy Completed NCT03481803 Phase 2 MS1819-SD
48 A Phase II, Multicenter, Parallel-Group, Active-Controlled, Randomized, Double-blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Different Doses of Creon IR in Subjects With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis Completed NCT02415959 Phase 2 Creon IR;Creon® (DR/GR)
49 An Open-Label Cross-over Study to Evaluate the Intraduodenal Delivery of Lipase, Protease and Amylase From Administration of VIOKASE16 in Chronic Pancreatitis Subjects With Exocrine Pancreatic Insufficiency (EPI). Completed NCT00559052 Phase 2 VIOKASE 16
50 An Open Label, Exploratory Study on the Effect of rhBSSL on the Fat Absorption in Patients With Cystic Fibrosis and Pancreatic Insufficiency Completed NCT00743483 Phase 2 rhBSSL

Search NIH Clinical Center for Exocrine Pancreatic Insufficiency

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Pancrelipase
Pancrelipase amylase
Pancrelipase protease

Cochrane evidence based reviews: exocrine pancreatic insufficiency

Genetic Tests for Exocrine Pancreatic Insufficiency

Anatomical Context for Exocrine Pancreatic Insufficiency

MalaCards organs/tissues related to Exocrine Pancreatic Insufficiency:

41
Testes, Pancreas, Bone, Liver, Bone Marrow, Small Intestine, Kidney
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Exocrine Pancreatic Insufficiency:
# Tissue Anatomical CompartmentCell Relevance
1 Pancreas Pancreatic Acini Acinar Cells Affected by disease, potential therapeutic candidate

Publications for Exocrine Pancreatic Insufficiency

Articles related to Exocrine Pancreatic Insufficiency:

(show top 50) (show all 1120)
# Title Authors PMID Year
1
13C-labeled mixed triglyceride breath test (13C MTG-BT) in healthy children and children with cystic fibrosis (CF) under pancreatic enzyme replacement therapy (PERT): a pilot study. 9 38
18817766 2008
2
Exocrine pancreatic insufficiency in the Eurasian dog breed--inheritance and exclusion of two candidate genes. 9 38
17302791 2007
3
Is exocrine pancreatic insufficiency in adult coeliac disease a cause of persisting symptoms? 9 38
17269988 2007
4
Does secretin-stimulated MRCP predict exocrine pancreatic insufficiency?: A comparison with noninvasive exocrine pancreatic function tests. 9 38
17016144 2006
5
Homozygous (TG)11 allele in intron 8 of the cystic fibrosis transmembrane conductance regulator (CFTR) gene has a protective role against bicarbonate decrease in pure pancreatic juice among Japanese male alcoholics. 9 38
15645646 2004
6
[New fecal markers: recent developments and perspectives]. 9 38
15550893 2004
7
Low fecal elastase: potentially related to transient small bowel damage resulting from enteric pathogens. 9 38
12604981 2003
8
Faecal elastase 1 concentration is a marker of duodenal enteropathy. 9 38
11806885 2002
9
[Maldigestion during chronic pancreatitis]. 9 38
11458612 2001
10
Comparison of fecal elastase-1 determination with the secretin-cholecystokinin test in patients with cystic fibrosis. 9 38
10192202 1999
11
Comparative clinical evaluation of the 13C-mixed triglyceride breath test as an indirect pancreatic function test. 9 38
9548629 1998
12
13C-starch breath test--comparative clinical evaluation of an indirect pancreatic function test. 9 38
9106982 1997
13
Intraduodenal free fatty acids rather than triglycerides are responsible for the release of CCK in humans. 9 38
8981511 1997
14
Immunoreactive elastase I: clinical evaluation of a new noninvasive test of pancreatic function. 9 38
8595714 1996
15
Maldigestion after total gastrectomy is associated with pancreatic insufficiency. 9 38
8607504 1996
16
[Measurement of fecal elastase 1 by immunoreactivity: a new indirect test of the pancreatic function]. 9 38
8761139 1996
17
Lack of accuracy of plasma alpha-amino nitrogen profiles as an indicator of exocrine pancreatic function both after continuous and bolus stimulation of the pancreas with secretin and cholecystokinin-pancreozymin. 9 38
7871858 1994
18
Adenovirus-mediated transfer of human lipase complementary DNA to the gallbladder. 9 38
8194711 1994
19
[The diagnostic value of the amino acid absorption test in detection of a disorder of exocrine pancreatic function]. 9 38
1636270 1992
20
Fecal isoamylase activity in patients with pancreatic diseases. 9 38
1704633 1991
21
Alcohol-related chronic exocrine pancreatic insufficiency: diagnosis and therapeutic management. A proposal for treatment by the Italian Association for the Study of the Pancreas (AISP) and the Italian Society of Alcohology (SIA). 38
30938130 2019
22
Fat digestibility in meat products: influence of food structure and gastrointestinal conditions. 38
30489160 2019
23
Pancreas-specific plasma amylase for assessment and diagnosis of chronic pancreatitis: New insights on an old topic. 38
31428420 2019
24
Risk Factors for Rapid Progression From Acute Recurrent to Chronic Pancreatitis in Children: Report From INSPPIRE. 38
31136562 2019
25
Lower Gastrointestinal Conditions: Malabsorption Syndromes. 38
31411845 2019
26
Acute Recurrent and Chronic Pancreatitis as Initial Manifestations of Cystic Fibrosis and Cystic Fibrosis Transmembrane Conductance Regulator-Related Disorders. 38
31268981 2019
27
Characterization of all the lipolytic activities in pancreatin and comparison with porcine and human pancreatic juices. 38
31288050 2019
28
Pancreas Divisum in Pediatric Acute Recurrent and Chronic Pancreatitis: Report From INSPPIRE. 38
29864067 2019
29
Association of multiple patient and disease characteristics with the presence and type of pain in chronic pancreatitis. 38
31314128 2019
30
Exocrine pancreatic insufficiency in distal pancreatectomy: incidence and risk factors. 38
31327560 2019
31
Exocrine Pancreatic Insufficiency Following Acute Pancreatitis: True Association or EPIphenomenon? 38
31076987 2019
32
Exocrine Pancreatic Insufficiency Following Acute Pancreatitis: Systematic Review and Meta-Analysis. 38
31161524 2019
33
Optimizing Clinical and Cost Outcomes for Patients on Enteral Nutrition Support for Treatment of Exocrine Pancreatic Insufficiency: Proceedings from an Expert Advisory Board Meeting. 38
31066618 2019
34
Superiority of endoscopic interventions over minimally invasive surgery for infected necrotizing pancreatitis: meta-analysis of randomized trials. 38
31220368 2019
35
Prehabilitation in patients undergoing pancreaticoduodenectomy: a randomized controlled trial. 38
31232076 2019
36
Hypertrophic osteoarthropathy presenting with joint pain in cystic fibrosis. 38
31216115 2019
37
The Etiology of Pancreatic Manifestations in Patients with Inflammatory Bowel Disease. 38
31247968 2019
38
Cirrhosis complicating Shwachman-Diamond syndrome: A case report. 38
31363473 2019
39
Inflammatory bowel disease in Shwachman-Diamond syndrome; is there an association? 38
31196706 2019
40
[Other specific types of diabetes and exocrine pancreatic insufficiency (Update 2019)]. 38
30980164 2019
41
Chronic Pancreatitis: Pediatric and Adult Cohorts Show Similarities in Disease Progress Despite Different Risk Factors. 38
30897605 2019
42
Bruising as the first sign of exocrine pancreatic insufficiency in infancy. 38
31086851 2019
43
Transient Exocrine Pancreatic Insufficiency in Children: An Existing Entity? 38
30633105 2019
44
Delivery of pancreatic digestive enzymes into the gastrointestinal tract by pancreatic exocrine tissue transplant. 38
30976035 2019
45
Correlation Between the Standard Pancreatic Elastase-1 Enzyme-Linked Immunosorbent Assay Test and the New, Rapid Fecal Pancreatic Elastase-1 Test for Diagnosing Exocrine Pancreatic Insufficiency. 38
30973468 2019
46
Sarcopenia associates with increased hospitalization rates and reduced survival in patients with chronic pancreatitis. 38
30665702 2019
47
Global epidemiology and holistic prevention of pancreatitis. 38
30482911 2019
48
Variations in gastrointestinal lipases, pH and bile acid levels with food intake, age and diseases: Possible impact on oral lipid-based drug delivery systems. 38
30926476 2019
49
Zinc deficiency in patients with chronic pancreatitis. 38
30774274 2019
50
Exocrine pancreatic function is preserved in systemic sclerosis. 38
30755261 2019

Variations for Exocrine Pancreatic Insufficiency

Expression for Exocrine Pancreatic Insufficiency

Search GEO for disease gene expression data for Exocrine Pancreatic Insufficiency.

Pathways for Exocrine Pancreatic Insufficiency

Pathways related to Exocrine Pancreatic Insufficiency according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.26 PTF1A PDX1 CFTR
2 9.47 SCT CCK

GO Terms for Exocrine Pancreatic Insufficiency

Biological processes related to Exocrine Pancreatic Insufficiency according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 generation of precursor metabolites and energy GO:0006091 9.32 PDX1 COX4I2
2 positive regulation of insulin secretion involved in cellular response to glucose stimulus GO:0035774 9.26 PDX1 CFTR
3 pancreas development GO:0031016 9.16 PTF1A PDX1
4 sperm capacitation GO:0048240 8.96 SPINK1 CFTR
5 exocrine pancreas development GO:0031017 8.62 PTF1A PDX1

Sources for Exocrine Pancreatic Insufficiency

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....